Latest news with #CLOV
Yahoo
06-08-2025
- Business
- Yahoo
Clover Health Investments Corp (CLOV) Q2 2025 Earnings Call Highlights: Surpassing Growth ...
Release Date: August 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Clover Health Investments Corp (NASDAQ:CLOV) reported significant membership growth of over 30% year-over-year, surpassing industry averages. The company achieved sustained adjusted profitability in Medicare Advantage, demonstrating effective execution of its strategy. Clover Health's technology-first care model, including the Clover Assistant, has shown to improve health outcomes, such as reducing hospitalizations and readmissions for chronic diseases. The company is well-positioned for future growth with a four-star payment year in 2026, providing a financial tailwind. Clover Health is expanding its technology platform to other risk-bearing entities, showing broad interest and uptake, which could drive additional revenue streams. Negative Points Clover Health is experiencing elevated cost trends within its Medicare Advantage book, similar to broader industry pressures. The company is facing variability in modeling performance due to the new Part D IRA changes, which could impact financial results. There are elevated pockets of utilization within supplemental benefits and Part B, which negatively impacted results. The competitive landscape remains challenging, with national players pulling back in certain areas, potentially affecting market dynamics. Clover Health's insurance benefit expense ratio (BER) increased year-over-year, reflecting higher costs and impacting profitability. Q & A Highlights Warning! GuruFocus has detected 4 Warning Signs with CLOV. Q: The MCR BER came in above expectations. How much conservatism is embedded in your raised guidance on the BER, and how much visibility do you have into how that trend will develop in the back half of the year? A: The increase in the BER guidance for the full year is mostly related to Part D and supplemental benefits, particularly dental. We have initiatives in place to monitor this going forward, and we believe there will be some relief on the Part D pressure from the IRA as we move into 2026. - Peter Kuipers, CFO Q: What are the drivers for the improvements in your SG&A or adjusted SG&A? Are you holding back on hiring or finding new efficiencies within the model? A: The improvements are mostly due to cost efficiencies. We initiated a company-wide cost initiative to rationalize the price and volume terms with our partnership contracts. As we are growing above the industry, we are renegotiating terms with partners to reflect our effective partnership. - Peter Kuipers, CFO Q: What kind of response have you been getting from the COPD white paper, and are there plans to publish similar papers? A: We are proud of the papers we are publishing, including the recent COPD white paper. We plan to continue producing such material as it highlights the benefits of using Clover Assistant, which is correlated with better diagnosis management and care. These results are also used to promote our offerings in the counterpart context. - Andrew Toy, CEO Q: Is the elevated cost trend you're seeing more localized to newer cohorts, or is it broad-based? Are there any geographical differences? A: The cohorts in our tech-first model are performing as expected. We do not see a specific split between new and returning members regarding Part D and supplemental benefits. Returning members are improving from an MCR and BER perspective as expected. - Peter Kuipers, CFO Q: How are competitors approaching the upcoming AP, and are there any differences in the competitive landscape compared to last year? A: Many national players are pulling back, especially in the PPO wider network where they struggle to deploy their managed care capabilities. This is an area where we are strong due to our technology. We feel well-placed for the coming growth season, especially with the financial tailwind of a four-star payment year in 2026. - Andrew Toy, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Business Wire
23-07-2025
- Business
- Business Wire
TotalEnergies - Angola: Start-up of BEGONIA and CLOV Phase 3 Offshore Projects
PARIS--(BUSINESS WIRE)-- TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE) announces the start of production from the BEGONIA and CLOV Phase 3 offshore projects, leveraging ullage in the PAZFLOR and CLOV floating production, storage and offloading units (FPSO) to add a total of 60,000 barrels a day of new production. These two subsea tie-back projects deliver additional production leveraging available capacity on existing FPSO's and as such have low marginal costs and low carbon intensities. BEGONIA, the first development on Block 17/06 TotalEnergies (30%, operator) announces the start of production from BEGONIA, the first inter-block development in Angola. A project made possible thanks to good cooperation between the Angolan concession holder Agencia Nacional de Petróleo, Gás e Biocombustíveis (ANPG), the partners of the block 17/06, Sonangol E&P (30%), SSI (27,5%), ETU Energias (7.5%), Falcon Oil (5%), and the partners of block 17 also operated by TotalEnergies. Located 150 kilometers off the Angolan coast, BEGONIA is a 30,000 barrels per day project consisting of five wells subsea tied back to the PAZFLOR FPSO. CLOV Phase 3, continued upsides on Block 17 TotalEnergies (38%, operator) also announces the first oil from CLOV Phase 3 in Block 17, in agreement with ANPG and its partners Equinor (22,16%), ExxonMobil (19%), Azule Energy (15.84%) and Sonangol E&P (5%). Located 140 kilometers from the Angolan coast, CLOV Phase 3 is a 30,000 barrels per day project consisting of four wells subsea tie-back to the CLOV FPSO. 'TotalEnergies, operator of Block 17 and 17/06, continues to actively deliver its low-cost and low-emissions developments to grow its upstream production by more than 3% in 2025,' stated Nicolas Terraz, President Exploration & Production at TotalEnergies. 'With BEGONIA and CLOV Phase 3, we are leveraging available production capacity in existing FPSOs of Block 17 (PAZFLOR and CLOV) while reducing costs and emissions.' 'Good news for the country, as those two First Oils will help Angola maintain its production levels above 1 million baril per day. BEGONIA is the first project between Blocks in Angola with a significant component of Local Content and CLOV 3 is a great achievement resulting from intense work between the concessionaire and the B17 contractor group, operated by TotalEnergies. Projects like these are extremely important as they prove the innovative spirit and dynamism of the oil sector in Angola,' declared Paulino Jerónimo, Chairman of the Board of Directors of the National Agency for Petroleum, Gas and Biofuels. *** About TotalEnergies in Angola TotalEnergies has been present in Angola since 1953 and today employs around 1,500 people across different business segments. With a diversified portfolio, deep offshore operated assets representing more than 45% of the country's oil production, service stations in partnership with Sonangol and renewable energy projects, TotalEnergies in Angola is a key player in supporting the country's sustainable energy transition. About TotalEnergies TotalEnergies is a global integrated energy company that produces and markets energies: oil and biofuels, natural gas, biogas and low-carbon hydrogen, renewables and electricity. Our more than 100,000 employees are committed to provide as many people as possible with energy that is more reliable, more affordable and more sustainable. Active in about 120 countries, TotalEnergies places sustainability at the heart of its strategy, its projects and its operations. @TotalEnergies TotalEnergies TotalEnergies TotalEnergies Cautionary Note The terms 'TotalEnergies', 'TotalEnergies company' or 'Company' in this document are used to designate TotalEnergies SE and the consolidated entities that are directly or indirectly controlled by TotalEnergies SE. Likewise, the words 'we', 'us' and 'our' may also be used to refer to these entities or to their employees. The entities in which TotalEnergies SE directly or indirectly owns a shareholding are separate legal entities. This document may contain forward-looking information and statements that are based on a number of economic data and assumptions made in a given economic, competitive and regulatory environment. They may prove to be inaccurate in the future and are subject to a number of risk factors. Neither TotalEnergies SE nor any of its subsidiaries assumes any obligation to update publicly any forward-looking information or statement, objectives or trends contained in this document whether as a result of new information, future events or otherwise. Information concerning risk factors, that may affect TotalEnergies' financial results or activities is provided in the most recent Universal Registration Document, the French-language version of which is filed by TotalEnergies SE with the French securities regulator Autorité des Marchés Financiers (AMF), and in the Form 20-F filed with the United States Securities and Exchange Commission (SEC). TotalEnergies Contacts Media Relations: +33 (0)1 47 44 46 99 l presse@ l @TotalEnergiesPR Investor Relations: +33 (0)1 47 44 46 46 l ir@
Yahoo
07-07-2025
- Business
- Yahoo
Craig-Hallum Reiterates a Buy Rating on Clover Health Investments (CLOV), Sets a $6 PT
Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the 13 Stocks Under $5 With High Upside Potential. In a report released on May 7, Matt Hewitt from Craig-Hallum reiterated a Buy rating on Clover Health Investments, Corp. (NASDAQ:CLOV) with a price target of $6.00. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. The company reported notable fiscal Q1 2025 results that support this optimistic outlook, with Medicare Advantage membership for the quarter reaching 103,418, representing a 30% year-over-year increase. Total revenue for fiscal Q1 2025 rose 33% year-over-year to $462 million, while adjusted EBITDA reached $26 million, reflecting a significant 279% year-over-year rise. Adjusted net income also grew 322% year-over-year to $25 million. In addition, Clover Health Investments, Corp. (NASDAQ:CLOV) reported a GAAP net loss of $1 million, compared to $19 million a year ago, suggesting a considerable improvement in its operations. Clover Health Investments, Corp. (NASDAQ:CLOV) is a physician enablement technology company that offers Medicare Advantage plans in the United States. It offers PPO and HMO Medicare Advantage plans in several US states. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
23-06-2025
- Business
- Yahoo
Canaccord Genuity Keeps Buy Rating on Clover Health (CLOV)
Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the 11 Best US Stocks to Invest in Under $5. On April 8, Canaccord Genuity analyst Richard Close reiterated a 'Buy' rating on Clover Health Investments, Corp. (NASDAQ:CLOV) with a price target of $4.50. According to the analyst, the final rate update is good news for Clover Health Investments, Corp. (NASDAQ:CLOV). Close believes this change will help the company and could also improve the managed care sector's overall sentiment. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. The company is expected to continue growing strongly in 2025. This growth will also help Clover Health Investments, Corp. (NASDAQ:CLOV) in 2026 as the company benefits from reimbursements tied to having a 4-Star rating. Canaccord Genuity will be looking at the competitive landscape closely as new plans for 2026 are introduced. Close noted that the positive rate update should improve the outlook for the managed care sector. Clover Health Investments, Corp. (NASDAQ:CLOV) is an American company that provides Medicare Advantage insurance plans. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-05-2025
- Business
- Yahoo
3 Stocks Under $10 in the Doghouse
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn't mean they're bargains though, and we urge investors to be careful as many have risky business models. Luckily for you, our mission at StockStory is to help you make money and avoid losses by sorting the winners from the losers. Keeping that in mind, here are three stocks under $10 to avoid and some other investments you should consider instead. Share Price: $4.17 Focusing on the silicon carbide and power semiconductor sectors, Amtech Systems (NASDAQ:ASYS) produces the machinery and related chemicals needed for manufacturing semiconductors. Why Is ASYS Risky? Customers postponed purchases of its products and services this cycle as its revenue declined by 7.9% annually over the last two years Historical operating margin losses point to an inefficient cost structure Negative returns on capital show that some of its growth strategies have backfired, and its shrinking returns suggest its past profit sources are losing steam Amtech's stock price of $4.17 implies a valuation ratio of 15.6x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than ASYS. Share Price: $3.12 Founded in 2014 to improve healthcare for America's seniors through technology, Clover Health (NASDAQ:CLOV) provides Medicare Advantage plans for seniors with a focus on affordable care and uses its proprietary Clover Assistant software to help physicians manage patient care. Why Are We Cautious About CLOV? Products and services are facing significant end-market challenges during this cycle as sales have declined by 28.7% annually over the last two years Weak customer trends over the past two years suggest it may need to improve its products, pricing, or go-to-market strategy Cash burn makes us question whether it can achieve sustainable long-term growth At $3.12 per share, Clover Health trades at 42.6x forward EV-to-EBITDA. Check out our free in-depth research report to learn more about why CLOV doesn't pass our bar. Share Price: $4.90 Pioneering the modern office copier and inventing technologies like Ethernet and the laser printer, Xerox (NASDAQ:XRX) provides document management systems, printing technology, and workplace solutions to businesses of all sizes across the globe. Why Do We Think XRX Will Underperform? Products and services are facing significant end-market challenges during this cycle as sales have declined by 6.7% annually over the last five years Diminishing returns on capital from an already low starting point show that neither management's prior nor current bets are going as planned High net-debt-to-EBITDA ratio of 6× increases the risk of forced asset sales or dilutive financing if operational performance weakens Xerox is trading at $4.90 per share, or 5x forward P/E. To fully understand why you should be careful with XRX, check out our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
